University of California San Francisco
Give to UCSF
<p>Yervoy, a new cancer drug that has been approved for the treatment of late-stage melanoma – and that is being used to treat other cancers in ongoing clinical trials – is based on a strategy for boosting the immune response developed and tested by scientists from UCSF and UC Berkeley.</p>
UCSF and Zcube have entered into a new agreement to license UCSF-developed microtechnology and support early research into new ways to deliver oral medications directly to a targeted site in the body.
UCSF Nobel laureate Elizabeth Blackburn is not ready to predict how long you will live. But she and her UCSF colleagues are exploring a feature within cells that is a kind of hourglass for aging.
Current and future scientists of all backgrounds will convene at UCSF Mission Bay on December 17 through a biotech networking event that draws students from City College of San Francisco.
A UCSF research collaboration with GE Healthcare has produced the first results in humans of a new technology that promises to rapidly assess the presence and aggressiveness of prostate tumors in real time, by imaging the tumor’s metabolism.
Amy Pyle, a veteran journalist with more than 20 years experience in communications, has joined UCSF as executive director of news and media relations.
UCSF Chancellor Susan Desmond-Hellmann, MD, MPH, will be inducted today into the American Academy of Arts and Sciences, alongside some of the world’s other most distinguished scholars, artists and institutional leaders.
Katherine Flores, a family physician and director of the UCSF Fresno Latino Center for Medical Education and Research, has been appointed a member of the new National Health Care Workforce Commission.
Stefan Habelitz, an engineer and materials scientist, is blazing a new research trail by investigating tooth enamel in the UCSF School of Dentistry's Marshall Lab, where researchers fruitfully focus on every facet of teeth, knowing they’re nothing to take for granted…
UCSF has hired two senior managers to strengthen the University’s research enterprise.
Larissa Podust, PhD, is working on a new drug for Chagas disease, a neglected scourge.
With innovation as the watchword, a biotech spinoff from the UCSF School of Pharmacy announced a $40 million Series A round of investment last week – hailed by an investor as “one of the largest first rounds of financing in some time.”